ClinicalTrials.gg

Program

Brentuximab Vedotin

Also written as “brentuximab vedotin”, “Brentuximab vedotin” and “SGN-35”.

Its studies are mostly in Hodgkin Disease · Lymphoma, Large-Cell, Anaplastic · Lymphoma, Large B-Cell, Diffuse · Lymphoma, T-Cell, Peripheral · Melanoma, led by 3 companies.

Furthest: phase 4, since Apr 6, 201037 company-led studies, 4 open or runningNext primary completion: Mar 31, 2028 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizer241 open or runningphase 3since Apr 6, 2010Feb 1, 2007none ahead
Takeda113 open or runningphase 4since Jul 1, 2013Dec 12, 2011Mar 31, 2028phase 4 · NCT06831370
Bristol-Myers Squibb20 open or runningphase 3since May 1, 2017Oct 13, 2015none ahead

Also a collaborator on its studies: Merck, Takeda Development Center Americas and Ono Pharmaceutical.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 22 studies since Feb 1, 2007.

  1. Jul 9, 2015Phase 2 study in Lupus Erythematosus, SystemicPfizer · NCT02533570 · 20 enrolled · United States
  2. Oct 7, 20152 phase 2 studiesPfizer · NCT02572167, NCT02594163
  3. Oct 13, 2015Bristol-Myers Squibb’s first study: phase 2 study in Non-Hodgkin's DiseaseNew to Bristol-Myers SquibbBristol-Myers Squibb · NCT02581631 · 145 enrolled · United States, Canada, France and more
  4. Oct 18, 2016Phase 2 study in Hodgkin DiseaseTakeda · NCT02939014 · 39 enrolled · China
  5. Nov 11, 2016Phase 2 study in Hodgkin DiseaseTakeda · NCT02979522 · 59 enrolled · United States, Brazil, Italy and more
  6. May 1, 2017Phase 3 study in Hodgkin DiseaseBristol-Myers Squibb · NCT03138499 · 23 enrolled · United States, Japan, Puerto Rico
  7. May 9, 2019Phase 2 study in Hodgkin DiseasePfizer · NCT03947255 · 12 enrolled · United States
  8. May 21, 2020Phase 3 study in Lymphoma, Large B-Cell, DiffusePfizer · NCT04404283 · 240 enrolled · United States, Australia, Belgium and more
  9. Sep 23, 2020Phase 2 study in Lymphoma, T-Cell, PeripheralPfizer · NCT04569032 · 82 enrolled · United States, France, Italy and more
  10. Oct 23, 2020Phase 2 study in MelanomaPfizer · NCT04609566 · 161 enrolled · United States
  11. Feb 7, 2022Phase 1 study in Acquired Immunodeficiency SyndromePfizer · NCT05244473 · United States
  12. Jun 30, 2022Phase 4 study in Lymphoma, T-CellTakeda · NCT05442554 · 10 enrolled · China
  13. Jan 4, 2023Phase 2 study in LymphomaTakeda · NCT05673785 · 52 enrolled · China
  14. Feb 14, 2025Phase 4 study in Hodgkin DiseaseTakeda · NCT06831370 · 124 planned · India

Ahead

  1. Mar 31, 2028Primary completion: phase 4 study in Hodgkin DiseaseTakeda · NCT06831370

TargetBeta

TNF →TNFRSF8 →read by rule
“An antibody-drug conjugate (ADC) directed against the tumor necrosis factor (TNF) receptor CD30 ”NCIt, by rule
“Tumor necrosis factor receptor superfamily member 8 binding agent”ChEMBL 37, by rule

Studies

All 37 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06831370Hodgkin Disease · India4RecruitingTakedaMar 31, 2028124
NCT05673785Lymphoma · China2Active, not recruitingTakedaApr 27, 202552
NCT05442554Lymphoma, T-Cell · China4CompletedTakedaAug 9, 202410
NCT05244473Acquired Immunodeficiency Syndrome · United States1WithdrawnPfizerMay 31, 20240
NCT04609566Melanoma · United States2CompletedPfizerFeb 3, 2026161
NCT04569032Lymphoma, T-Cell, Peripheral · United States, France, Italy and more2CompletedPfizerMay 9, 202482
NCT04404283Lymphoma, Large B-Cell, Diffuse · United States, Australia, Belgium and more3Active, not recruitingPfizerJan 23, 2026240
NCT03947255Hodgkin Disease · United States2TerminatedPfizerNov 6, 202212
NCT03138499Hodgkin Disease · United States, Japan, Puerto Rico3TerminatedBristol-Myers SquibbFeb 22, 202123
NCT02979522Hodgkin Disease · United States, Brazil, Italy and more2Active, not recruitingTakedaMay 5, 202059
NCT02939014Hodgkin Disease · China2CompletedTakedaAug 2, 201839
NCT02594163Diffuse Large B-cell Lymphoma Refractory · United States, Czechia, France and more2TerminatedPfizerSep 201725
NCT02581631Non-Hodgkin's Disease · United States, Canada, France and more2CompletedBristol-Myers SquibbJan 16, 2020145
NCT02572167Hodgkin Disease · United States2CompletedPfizerMar 1, 201893
NCT02533570Lupus Erythematosus, Systemic · United States2TerminatedPfizerJun 5, 201720
NCT01990534Hodgkin Disease · Czechia, Germany, Malaysia and more4CompletedTakedaMar 24, 201660
NCT01950364Hodgkin Disease · Belgium, Lithuania, Spain1CompletedTakedaOct 201420
NCT01925612Lymphoma, B-Cell · United States, Czechia, Italy and more2TerminatedPfizerMay 1, 201787
NCT01909934Lymphoma · Belgium, Croatia, Czechia and more4CompletedTakedaMay 4, 202150
NCT01874054Hodgkin Disease · United States2CompletedPfizerDec 201555
NCT01777152Lymphoma, Large-Cell, Anaplastic · United States, Australia, Canada and more3CompletedPfizerAug 15, 2018452
NCT01712490Hodgkin Disease · United States, Australia, Belgium and more3CompletedTakedaApr 20, 20171,334
NCT01716806Hodgkin Disease · United States, Canada2CompletedPfizerApr 7, 2023131
NCT01578499Lymphoma, Primary Cutaneous Anaplastic Large Cell · United States, Australia, Austria and more3CompletedTakedaMay 31, 2016131
NCT01492088Recurrence · United States, France, Germany and more2CompletedTakedaOct 12, 201636
NCT01461538Precursor Cell Lymphoblastic Leukemia-Lymphoma · United States2CompletedPfizerDec 201484
NCT01421667Lymphoma, B-Cell · United States, Canada2CompletedPfizerJun 2015176
NCT01309789Lymphoma, Large-Cell, Anaplastic · United States, United Kingdom1CompletedPfizerApr 201339
NCT01100502Hodgkin Disease · United States, Bulgaria, Czechia and more3CompletedPfizerAug 31, 2014329
NCT01060904Hodgkin Disease · United States, Canada1CompletedPfizerSep 201251
NCT01026415Carcinoma · United States1CompletedPfizerMay 201273
NCT01026233Hodgkin Disease · United States, Germany1CompletedPfizerAug 201052
NCT00947856Hodgkin Disease · United States, France2CompletedPfizerMar 2013110
NCT00866047Lymphoma, Large-Cell, Anaplastic · United States, Belgium, Canada and more2CompletedPfizerAug 201058
NCT00848926Hodgkin Disease · United States, Belgium, Canada and more2CompletedPfizerAug 2010102
NCT00649584Hodgkin Disease · United States1TerminatedPfizerFeb 201044
NCT00430846Lymphoma, Non-Hodgkin · United States1CompletedPfizerJul 200945

How it is read

Names in the registry

  • “brentuximab vedotin”, 27 entries
  • “Brentuximab vedotin”, 7 entries
  • “Brentuximab Vedotin”, 7 entries
  • “SGN-35”, 2 entries
  • “Brentuximab vedotin and rifampicin”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.